arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

RxSight, Inc.

RXST
$6.24 ▲ +0.17 (+2.80%) at close
Industrials ·Ophthalmic Goods ·USOphthalmic Goods
6 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
18
Health
Poor
Bearish
auto_awesome

Analytical Summary

RxSight, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $254.9M
Dividend Yield
Revenue Growth -3.9%
Op. Margin -35.8%
ROIC -17.5%
FCF / Share $-0.47
Trailing P/E
Price / Book 0.9x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

6-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$134.48M
↓ -3.9%
Net Income Profit after all expenses
$-38.94M
↓ -41.8%
Operating Margin Operating profit as % of sales
-35.8%
↓ -36.0% 7th
FCF / Share Free cash flow per share
$-0.47
↑ +17.8%
Long-Term Debt Long-term obligations
$0.00
↓ -100.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
8
Returns
31
Financial Health
2
Cash Quality
40

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 6 years · 24 quarters